Common blood changes not independent predictor of adverse outcomes for kidney disease patients

Aug 26, 2010

Fluctuations in blood composition that often arise from commonly used therapies among kidney disease patients are not an independent predictor of adverse outcomes for European hemodialysis patients, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that although hemoglobin variability is common in kidney disease patients, it does not appear to increase their likelihood of dying early.

Research has generated conflicting results on the health impacts that may occur when a person experiences variability in levels of hemoglobin (the component of blood that transports oxygen throughout the body) after taking erythropoiesis stimulating agents (ESAs). These drugs are commonly used to treat in patients with . Unfortunately, ESAs can increase the risk of vascular complications and possibly death when used to boost kidney disease patients' hemoglobin levels to what is considered normal (> 13 g/dL) in the general population. In addition, kidney disease patients often have significant fluctuations in hemoglobin levels when using ESAs.

To see if variability of hemoglobin levels over time may have a negative effect on a patient's health, Kai-Uwe Eckardt, MD (University of Erlangen-Nuremberg, Germany) and his colleagues examined data from 5037 European treated over two years.

"We were able to establish that variability in hemoglobin levels experienced by many hemodialysis patients, per se, does not appear to increase the risk of ," said Dr. Eckardt. However, the study did find that patients with consistently low levels of hemoglobin (<11 g/dl) had 2.34-times the risk of dying during the study period; those whose hemoglobin levels fluctuated between normal and <11 g/dl had 1.74-times the risk of dying during the study period.

Explore further: Sierra Leone ends anti-Ebola lockdown after three days

More information: The article, entitled "Hemoglobin Variability Does Not Predict Mortality in European Hemodialysis Patients," will appear online on August 26, 2010, doi:10.1681/ASN.2009101017

Related Stories

Recommended for you

US Ebola patient's health improves again

2 hours ago

An American healthcare worker who contracted the dangerous Ebola virus while working in Sierra Leone has improved and is now listed in fair condition, hospital officials said Monday.

Endoscopes linked to outbreak of drug-resistant E. coli

3 hours ago

An outbreak of a novel Escherichia coli (E. coli) strain resistant to antibiotics has been linked to contaminated endoscopes in a Washington state hospital. The study indicates that industry standard clea ...

Fighting back against superbugs

5 hours ago

Antibiotics—and antibiotic resistance—are in the news once again, with announcements by McDonald's and Costco that they will eliminate antibiotics that are important to human medicine from use in the ...

Harnessing the power of microbes as therapeutics

6 hours ago

A new report recently released by the American Academy of Microbiology discusses how specific microbes can be modified to enhance their therapeutic potential for treating human diseases such as cancer and antibiotic resistant ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.